Permeability of gadolinium-DTPA through two types of hemodialysis membrane

Investigative Radiology

Volumn 33, Issue 10, 1998, Pages 734-737

  Ueda, Jun ^a   Furukawa, Tomoaki ^a   Yamamoto, Tadatsuka ^a   Sakaguchi, Katsuhiko ^a   Araki, Yutaka ^b  

^a SUMITOMO HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Elimination rate; Gadolinium diethylenetriamine penta acetic acid (Gd DTPA); Hemodialysis; Hemodialysis membrane; Magnetic resonance imaging

Indexed keywords

CELLULOSE ACETATE; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DIALYSIS MEMBRANE; DRUG ELIMINATION; DRUG PENETRATION; FEMALE; HOLLOW FIBER MEMBRANE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0032471620     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199810000-00004     Document Type: Article

References (18)

1. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of Gd-DTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16:167.
2. Choyke PL, Frank JA, Webb D, Filling-Katz MR, Case report: Gadopentetate dimeglumine-enhanced MRI in an anephric patient on dialysis. Clin Radiol 1990;41:430.
3. Krahe T, Gotz R, Lackner K, et al. Pharmacokinetics of Gd-DTPA in the presence of chronic renal insufficiency requiring dialysis. Fortschr Rontgenstr 1992;156:523.
4. Barnhart JL, Kuhnert N, Douglas BA, Berk RN. Biodistribution of GdCl and Gd-DTPA and their influence on proton magnetic relaxation in rat tissues. Magn Reson Imaging 1987;5:221.
5. Carvlin MJ, De Simone DN, Meeks MJ. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent. Invest Radiol 1992;27:516.
6. Goldstein HA, Kashanian FK, Blutetti RF, Holyoak WL, Hugo FP, Blumenfield DM. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 1990;174:17.
7. Niendorf HP, Dinger JC, Haustein J, Cornelius I, Alhassan A, Clauss W. Tolerance data of Gd-DTPA: A review. Eur J Radiol 1991;13: 15.
8. Jordan RM, Mintz D. Fatal reaction to gadopentetate. AJR 1995;164: 743.
9. Arsenault TM, King BF, Marsh JW, et al. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: Retrospective analysis of an initial experience. Mayo Clin Proc 1996; 71:1150.
10. Haustein J, Niendorf HP, Krestin G, et al. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. Invest Radiol 1992;27:153.
11. Schuhmann-Giampieri G, Claub W, Krestin GP. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. In: Bydder G, Felix R, Buchelor E, et al, eds. Contrast media in MRI. Brinklaan, The Netherlands: Medicom, 1990;313-319.
12. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991;26:975.
13. Harpur ES, Worah D, Hals P-A, Holz E, Furuhama K, Noruma H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 1993;28:828.
14. Leander P, Allard M, Caille JM, Golman K. Early effect of gadopentate and iodinated contrast media on rabbit kidneys. Invest Radiol 1992;27:922.
15. Cacheris WP, Quay SC, Racklage SM. The relationship between thermodynamics and the toxicity of gadolinium compounds. Magn Reson Imaging 1990;8:467.
16. Furukawa T, Ueda J, Higashino K, Takahashi S, Sakaguchi K, Imai T. Permeability of contrast media through hemodialysis membrane. Acta Radiol 1997;38:918.
17. Choyke PL, Girton ME, Vaughan EM, Frank JA, Austin III HA. Clearance of gadolinium chelates by hemodialysis: An in vitro study. JMRI 1995;4:470.
18. Chang CA. Magnetic resonance imaging contrast agents: Design and physicochemical properties of gadodiamide. Invest Radiol 1993:28: S21.